NCCN 指南 带有证据块的前列腺癌指南4.2022 版.pdf,® NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Prostate Cancer NCCN Evidence BlocksTM Version 4.2022 — May 10, 2022 NCCN.org Continue ® ® ® Version 4.2022, 05/10/22 © 202
NCCN临床实践指南:前列腺癌(2022.V2)更新解读[J]. 临床外科杂志, 2022, 30(1): 31-33. LIN Qi, KONG Jiajin, CHEN Wei.. National comprehensive cancer network clinical practice guidelines: updated interpretation of prostate cancer [J]. JOURNAL OF CLINICAL SURGERY, 2022, 30(1): 31-33. 使用...
[1] Prostate cancer-NCCN Guidelines Version 1.2023. [2] Prostate Cancer-NCCN Guidelines Version 4.2022. [3] Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metas...
参考文献 [1]NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer,Version 2.2023. [2]2022 ASCO-GU,Abstract 11. [3]2023 ASCO-GU,LBA 16. [4]2023 ASCO,Abstract 5012. [5]de Bono J, et al. N Engl J Med,2020...
NCCN GUIDELINES ® 2022 FOR PATIENTS Esophageal Cancer Presented with support from: Available online at NCCN.org/patients Ü Esophageal Cancer It's easy to get lost in the cancer world Let NCCN Guidelines for Patients® be your guide 9 Step-by-step guides to the cancer care options...
[3] Prostate Cancer-NCCN Guidelines Version 2.2023. [4] de Bono JS, Mehra N, Scagliotti GV, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet ...
Version 1.2023, 10/26/2022 ? 2022 National Comprehensive Cancer Network (NCCN ), All rights reserved. NCCN Guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN. NCCN Guidelines Index ...
[3] NCCN Clinical Practice Guidelines in Oncology:Prostate Cancer Early Detection(Version 1.2023) 编辑:Gardenia 审校:Rudolf 执行:Uni 本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容,不能以任何方式取代专业的医疗指导,也不应被视为诊疗建议。如该等信息被用于了...
1、2020 NCCN前列腺癌指南V2版更新National ComprehensiveCancer Network"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)Prostate CancerVersion 2.2020 May 21. 2020NCCN.orgContinue5月15日,FDA加速批准卢卡帕利(Rucaparib )用于治疗预先接 受过雄激素受体靶向疗法和紫杉烷类化疗的BRCA突变(胚系和/或 ...
Methods: We retrospectively reviewed all listed references in the National Comprehensive Cancer network (NCCN) Prostate cancer guidelines version 2.2021. All cited papers were reviewed for patient level data on racial or ethnic distribution in the study population. Subgroup analysis was performed by ...